Back to Peptides

Elamipretide

Mitochondrial Support

Elamipretide is a mitochondria-targeted tetrapeptide developed to support mitochondrial health and energy production. It binds cardiolipin in the inner mitochondrial membrane, preserving mitochondrial structure and reducing oxidative stress. Elamipretide has shown benefit in patients with primary mitochondrial myopathies, cardiovascular disease, and other conditions associated with impaired energy metabolism. It is commonly used in protocols that involve SS-31 or serve as follow-up to NAD+ and MOTS-c-based mitochondrial repair stacks.

Reconstitute
2 mL BAC + 2mg vial
10 mcg/unit
Daily Range
20–40 mg Subcutaneous (SQ)
Once daily
Standard Dose
40 mg
Cycle
4–8 weeks
then reassess
Mitochondrial DysfunctionPeptideMitochondrial Medicine

Dosing & Reconstitution Guide

IV dosing is critical for safety. Do not exceed 140mg daily in clinical studies. Monitor for infusion reactions and report any adverse events immediately.

Standard / Gradual Approach

standard
PhaseDoseVolume
Week 170mg
Week 2100mg
Week 3140mg
Week 4140mg

Protocol Summary

Subcutaneous (SQ): Once daily · Dose range 2040 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Administered daily for 4–6 weeks depending on use case. May be extended up to 12 weeks in chronic mitochondrial dysfunction protocols. Used with or after NAD+ and SS-31 in mitochondrial support stacks. Cycle breaks of 4 weeks are commonly used.

🧪 Quick Start

Potential Benefits & Use Cases

Elamipretide is an investigational drug in most jurisdictions. Use only under clinical supervision or approved research protocols.
Supports mitochondrial function by reducing oxidative stress and enhancing ATP production
May improve cellular energy production, muscle endurance, and organ function
Studied for neurodegenerative diseases, cardiovascular health, and age-related mitochondrial decline
Clinical data Strong preclinical Limited data

Mechanism of Action

Selectively targets mitochondria, stabilizing cardiolipin to enhance electron transport chain efficiency
Reduces reactive oxygen species (ROS), decreasing oxidative damage and cellular apoptosis
Improves ATP production, supporting muscle function, cognition, and organ health

Lifestyle & Optimization

timing

Consistent daily dosing.

diet

Consume antioxidant-rich foods (berries, leafy greens, nuts). Minimize oxidative stress through lifestyle choices.

exercise

Maintain moderate exercise routine to support mitochondrial function.

sleep

Ensure 7–9 hours of sleep nightly.

Side Effects & Safety

Common Side Effects

Mild nausea
Transient fatigue
Localized injection discomfort

Contraindications & Warnings

Not recommended for individuals with uncontrolled metabolic disorders without supervision
Long-term safety studies are still ongoing; periodic monitoring is advised

Long-Term Safety Data

Limited human trials available, but early results suggest a favorable safety profile

🧮 Dose Calculator

Concentration
10.0
mcg/unit
Draw Volume
50
units (0.500 mL)
For a 500 mcg dose, draw 50 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
Rapid absorption after subcutaneous administration.
Oral Administration
Not available due to poor oral bioavailability.
Intranasal
Not specified
Half-Life
4-6 hours
Degradation
Predominantly metabolized by renal pathways.
Tissue Specificity
Targets mitochondrial tissues, especially muscle and heart.
⚗️

Peptide Details

Molecular Weight
751
Formula
C41H72N14O8S2
Sequence
D-Arg-Dmt-Lys-Phe-NH2
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
Store at 2-8°C if provided as lyophilized powder. If supplied as solution, maintain at 2-8°C and protect from light. Do not freeze. Solution is typically stable for 30 days post-opening when refrigerated.
Reconstituted (Mixed)
Refrigerate at 2–8°C after reconstitution. Use within 28 days.